I recently presented a paper on ‘How do networks affect knowledge generation for drug development? – A study of investigator networks, knowledge domains, and knowledge generation’ at the Annual Meeting of Technology, Innovation, and Entrepreneurship Division (TIE Kommission) of the German Academic Association for Business Research (VHB) which took place at the University of Koblenz-Landau.

In this paper my co-authors Pablo D’Este (INGENIO Valencia), Maureen McKelvey (University of Gothenburg), and Anne Assmus (University of Passau) and myself analyze whether the interplay of structural holes and actors’ knowledge domains affects the production of new scientific knowledge in clinical trials.